Your browser is no longer supported. Please, upgrade your browser.
Settings
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own0.70% Shs Outstand88.33M Perf Week2.13%
Market Cap7.13B Forward P/E424.63 EPS next Y0.19 Insider Trans-35.82% Shs Float87.44M Perf Month14.33%
Income-194.10M PEG- EPS next Q0.12 Inst Own- Short Float8.38% Perf Quarter35.78%
Sales67.10M P/S106.20 EPS this Y-54.60% Inst Trans-0.25% Short Ratio7.31 Perf Half Y68.82%
Book/sh3.93 P/B20.53 EPS next Y112.00% ROA-35.60% Target Price95.31 Perf Year93.85%
Cash/sh5.79 P/C13.95 EPS next 5Y40.10% ROE-61.90% 52W Range38.43 - 83.84 Perf YTD3.98%
Dividend- P/FCF- EPS past 5Y-34.70% ROI-46.80% 52W High-3.77% Beta0.19
Dividend %- Quick Ratio14.40 Sales past 5Y-28.00% Gross Margin99.30% 52W Low109.94% ATR3.12
Employees400 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)58.34 Volatility4.89% 4.22%
OptionableYes Debt/Eq1.05 EPS Q/Q70.40% Profit Margin- Rel Volume1.03 Prev Close78.56
ShortableYes LT Debt/Eq1.05 EarningsFeb 13 AMC Payout- Avg Volume1.00M Price80.68
Recom1.60 SMA205.14% SMA509.07% SMA20039.27% Volume1,027,683 Change2.70%
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Oct-04-16Resumed Leerink Partners Outperform $70
Jun-29-16Initiated H.C. Wainwright Buy $80
Oct-12-15Reiterated Leerink Partners Outperform $67 → $71
Oct-08-15Reiterated Piper Jaffray Overweight $86 → $96
Sep-16-15Reiterated Piper Jaffray Overweight $82 → $86
Aug-18-15Resumed Jefferies Buy
May-22-15Reiterated Piper Jaffray Overweight $56 → $64
May-22-15Reiterated Nomura Buy $61 → $69
Mar-04-15Initiated Barclays Overweight $60
Feb-10-15Reiterated Deutsche Bank Buy $35 → $45
Feb-05-15Initiated Robert W. Baird Outperform $40
Jan-09-15Reiterated Deutsche Bank Buy $25 → $35
Feb-10-14Reiterated Oppenheimer Outperform $15 → $19
Jan-11-18 10:17AM  Elagolix May Advance the Treatment Paradigm in Womens Health Market Realist
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
Jan-09-18 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Jan-08-18 05:52AM  Should You Be Concerned About Neurocrine Biosciences Incs (NASDAQ:NBIX) -54.35% Earnings Decline? Simply Wall St.
Jan-07-18 01:01PM  Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer PR Newswire
01:00PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones PR Newswire
Jan-02-18 04:01PM  Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-17 07:55AM  Is Neurocrine Biosciences Incs (NASDAQ:NBIX) Balance Sheet A Threat To Its Future? Simply Wall St.
Dec-19-17 11:42AM  Why Biotech Acadia May Be Undervalued By 40% Investopedia
Dec-15-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-13-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-12-17 08:10AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-11-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-07-17 01:15PM  Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire
08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-05-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-04-17 04:01PM  Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms PR Newswire
Nov-29-17 04:01PM  Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-28-17 08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-21-17 01:15PM  Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
08:15AM  Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-20-17 04:01PM  Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-16-17 09:42AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-15-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-14-17 01:34PM  Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-09-17 04:01PM  INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association PR Newswire
Nov-08-17 01:15PM  Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
Nov-07-17 10:12PM  Edited Transcript of NBIX earnings conference call or presentation 1-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
04:01PM  Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress PR Newswire
07:55AM  Neurocrine stock rockets to a record on sales beatbut can it last? MarketWatch
Nov-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Alnylam Pharmaceuticals ACCESSWIRE
03:00AM  Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating Investor's Business Daily
Nov-02-17 05:00PM  NBIX: INGREZZA® Revenues Way Ahead of Forecasts In 3Q17 Zacks Small Cap Research +19.45%
01:48PM  Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch Benzinga
01:10PM  Here's Why Neurocrine Biosciences Is Soaring Motley Fool
09:35AM  Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers TheStreet.com
08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-01-17 05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:31PM  Neurocrine reports 3Q loss Associated Press
04:01PM  Neurocrine Biosciences Reports Third Quarter 2017 Results PR Newswire
01:10PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
12:00PM  AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain PR Newswire
Oct-31-17 01:15PM  Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference PR Newswire
Oct-30-17 08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:30AM  Corporate News Blog - AbbVie Gets US FDA Priority Review for Elagolix for the Management of Endometriosis and Associated Pain ACCESSWIRE
Oct-27-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:00AM  AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain PR Newswire
Oct-25-17 04:01PM  Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome PR Newswire
08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-24-17 01:23PM  Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results PR Newswire
Oct-23-17 04:56PM  Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome PR Newswire
08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-18-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-16-17 01:23PM  How Is Neurocrine Biosciences Positioned Now? Market Realist
09:43AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-13-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-12-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-10-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-06-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-05-17 09:18AM  UPDATED: Neurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug MarketWatch
08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:00AM  Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) PR Newswire
Sep-25-17 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-22-17 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals ACCESSWIRE
03:00AM  Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91 Investor's Business Daily
Sep-18-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-15-17 09:25AM  Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress PR Newswire
Sep-12-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-11-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-06-17 02:00PM  Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference PR Newswire
08:01AM  AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain PR Newswire
07:37AM  Behind Bioverativs Analyst Recommendations This September Market Realist
Sep-02-17 08:08AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-01-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-30-17 01:00PM  Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference PR Newswire
03:00AM  Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82 Investor's Business Daily
Aug-29-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-28-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-25-17 08:01AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. ACCESSWIRE
Aug-24-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-23-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-21-17 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-18-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-17-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-14-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Aug-12-17 09:50PM  Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
01:15AM  Edited Transcript of NBIX earnings conference call or presentation 3-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:04AM  IHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two out of three available IHS Markit categories. Markit
Aug-10-17 08:04AM  IHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category. Markit
07:10AM  Featured Company News - Mylan Launches Avonza(TM) in India ACCESSWIRE
Aug-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics ACCESSWIRE
Aug-04-17 01:00PM  NBIX: Strong Start to INGREZZA® Launch Zacks Small Cap Research +9.54%
Aug-03-17 05:41PM  Neurocrine reports 2Q loss Associated Press
04:01PM  Neurocrine Biosciences Reports Second Quarter 2017 Results PR Newswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ?? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OBrien Christopher FlintChief Medical OfficerJan 16Sale79.141,750138,49950,723Jan 18 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerJan 16Sale79.121,625128,56379,316Jan 18 04:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 16Sale78.893,750295,820336,357Jan 18 04:09 PM
Gano KyleChief Business Development OffJan 16Sale79.051,625128,46074,871Jan 18 04:08 PM
Bozigian Haig P.Chief Development OfficerJan 16Sale79.121,625128,575131,226Jan 18 04:07 PM
Lippoldt DarinChief Legal OfficerJan 03Option Exercise18.151,97935,91915,136Jan 04 04:07 PM
Lippoldt DarinChief Legal OfficerJan 03Sale79.361,979157,05313,157Jan 04 04:07 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Option Exercise15.4518,084279,39831,101Jan 04 04:05 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Sale77.5218,0841,401,82313,017Jan 04 04:05 PM
Lippoldt DarinChief Legal OfficerDec 28Option Exercise18.1515,237276,55228,394Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 28Sale75.0015,2371,142,77513,157Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 08Option Exercise18.152,95553,63316,112Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 08Sale75.002,955221,62513,157Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 04Option Exercise18.156,279113,96419,436Dec 06 04:59 PM
Lippoldt DarinChief Legal OfficerDec 04Sale75.046,279471,16013,157Dec 06 04:59 PM
LYONS GARY ADirectorDec 01Sale72.9210,000729,182272,066Dec 05 04:31 PM
Lippoldt DarinChief Legal OfficerNov 15Option Exercise18.159,900179,68523,057Nov 17 04:29 PM
Lippoldt DarinChief Legal OfficerNov 15Sale73.059,900723,19113,157Nov 17 04:29 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 08Sale74.5830,0002,237,34377,691Nov 13 04:15 PM
Gano KyleChief Business Development OffNov 02Option Exercise8.6624,818214,81086,714Nov 06 04:44 PM
OBrien Christopher FlintChief Medical OfficerNov 02Option Exercise8.6652,817457,32094,272Nov 06 04:45 PM
OBrien Christopher FlintChief Medical OfficerNov 02Sale69.7152,8173,681,64148,973Nov 06 04:45 PM
Gano KyleChief Business Development OffNov 02Sale71.0524,8181,763,31973,246Nov 06 04:44 PM
OBrien Christopher FlintChief Medical OfficerOct 02Option Exercise8.656,92559,90155,898Oct 03 07:14 PM
OBrien Christopher FlintChief Medical OfficerOct 02Sale61.046,925422,70248,973Oct 03 07:14 PM
Gano KyleChief Business Development OffSep 06Option Exercise8.654,60739,85177,853Sep 08 02:58 PM
Bozigian Haig P.Chief Development OfficerSep 06Option Exercise13.3426,250350,138144,601Sep 08 02:58 PM
Lippoldt DarinChief Legal OfficerSep 06Option Exercise18.151001,81513,257Sep 08 02:59 PM
Gano KyleChief Business Development OffSep 06Option Exercise8.6520,393176,39993,639Oct 03 07:13 PM
Gano KyleChief Business Development OffSep 06Sale60.0020,3931,223,58073,246Oct 03 07:13 PM
Bozigian Haig P.Chief Development OfficerSep 06Sale60.0026,2501,575,000129,601Sep 08 02:58 PM
Lippoldt DarinChief Legal OfficerSep 06Sale60.001006,00013,157Sep 08 02:59 PM
Gano KyleChief Business Development OffSep 06Sale60.004,607276,42073,246Sep 08 02:58 PM
OBrien Christopher FlintChief Medical OfficerSep 05Option Exercise8.6652,817457,395101,790Sep 07 05:55 PM
OBrien Christopher FlintChief Medical OfficerSep 05Sale57.5052,8173,036,97848,973Sep 07 05:55 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 09Option Exercise5.7615,35488,439123,045Aug 14 12:29 PM
Lippoldt DarinChief Legal OfficerAug 09Option Exercise18.155,00090,75018,157Aug 14 12:30 PM
Lippoldt DarinChief Legal OfficerAug 09Sale55.005,000275,00013,157Aug 14 12:30 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 09Sale55.0015,354844,470107,691Aug 14 12:29 PM
Bozigian Haig P.Chief Development OfficerAug 04Option Exercise7.0545,000317,200154,601Aug 08 05:44 PM
Bozigian Haig P.Chief Development OfficerAug 04Sale50.0022,5001,125,000129,601Aug 08 05:44 PM
OBrien Christopher FlintChief Medical OfficerJul 27Option Exercise8.658,73475,54957,707Jul 31 04:29 PM
OBrien Christopher FlintChief Medical OfficerJul 27Sale50.008,734436,70048,973Jul 31 04:29 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 23Sale53.3910,000533,900107,691May 24 04:13 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Option Exercise15.454,98076,94117,997May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Sale54.004,980268,92013,017May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Option Exercise15.454,98076,94117,997May 23 04:34 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise18.1510,000181,50023,157May 23 04:34 PM
OBrien Christopher FlintChief Medical OfficerMay 18Option Exercise6.36105,634671,915154,607May 23 04:36 PM
OBrien Christopher FlintChief Medical OfficerMay 18Sale53.32105,6345,632,40548,973May 23 04:36 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Sale53.264,980265,23513,017May 23 04:34 PM
Lippoldt DarinChief Legal OfficerMay 18Sale53.2710,000532,70013,157May 23 04:34 PM
Nevinny Corinne HDirectorMay 05Sale53.985,000269,90034,603May 08 08:22 PM
Nevinny Corinne HDirectorMay 03Option Exercise3.4015,00051,00040,555May 05 01:26 PM
POPS RICHARD FDirectorMay 03Option Exercise3.4015,00051,00030,454May 05 01:27 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Option Exercise2.5921,73956,304354,346May 03 06:42 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 02Sale55.0010,000550,000117,691May 03 06:43 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Sale53.2321,7391,157,167332,607May 03 06:42 PM
Gano KyleChief Business Development OffMay 01Option Exercise2.5915,00038,85088,246May 03 06:41 PM
Gano KyleChief Business Development OffMay 01Sale54.0015,000810,00073,246May 03 06:41 PM
MOLLICA JOSEPH ADirectorApr 12Option Exercise3.4020,00068,00057,354Apr 13 05:32 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 12Sale50.4213,065658,77413,017Apr 13 04:56 PM
OBrien Christopher FlintChief Medical OfficerApr 12Sale50.4213,065658,77448,973Apr 13 04:56 PM
Lippoldt DarinChief Legal OfficerApr 12Sale50.4213,065658,77413,157Apr 13 04:55 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 12Sale50.4213,065658,774127,691Apr 13 04:54 PM
Gano KyleChief Business Development OffApr 12Sale50.4213,065658,77473,246Apr 13 04:53 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 12Sale50.4219,596988,085332,607Apr 13 04:53 PM
Bozigian Haig P.Chief Development OfficerApr 12Sale50.4213,065658,774129,601Apr 13 04:52 PM
LYONS GARY ADirectorFeb 14Option Exercise3.4015,00051,000282,066Feb 15 06:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Option Exercise2.5964,161166,177314,703Feb 08 07:37 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale44.651325,8941,222Feb 08 07:40 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale44.621325,8901,222Feb 08 07:39 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale44.611165,1751,082Feb 08 07:41 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale43.1496341,544117,666Feb 08 07:43 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale43.1372731,356115,756Feb 08 07:44 PM
Gano KyleChief Business Development OffFeb 06Sale43.1572731,37061,311Feb 08 07:42 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale43.1572731,3700Feb 08 07:41 PM
OBrien Christopher FlintChief Medical OfficerFeb 06Sale43.171,20652,06337,038Feb 08 07:40 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale43.1382135,4100Feb 08 07:39 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale43.1182135,3930Feb 08 07:40 PM
Coughlin Timothy PChief Financial OfficerFeb 06Sale43.1496341,544137,961Feb 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale43.183,010129,972250,542Feb 08 07:37 PM
Coughlin Timothy PChief Financial OfficerFeb 03Sale42.551,50063,825136,324Feb 06 07:19 PM
Bozigian Haig P.Chief Development OfficerFeb 03Sale42.571,37558,534116,079Feb 06 07:19 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 03Sale42.553,125132,969247,802Feb 06 07:18 PM
Gano KyleChief Business Development OffFeb 03Sale42.571,37558,53460,113Feb 06 07:18 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 03Sale42.561,37558,520114,558Feb 06 07:17 PM
OBrien Christopher FlintChief Medical OfficerFeb 03Sale42.501,50063,75035,044Feb 06 07:16 PM
RASTETTER WILLIAM HDirectorFeb 01Option Exercise2.1725,00054,25025,000Feb 02 07:29 PM
RASTETTER WILLIAM HDirectorFeb 01Sale42.2810,750454,51014,250Feb 02 07:29 PM